Holding META into earnings has been a rollercoaster I wouldn't wish on anyone. The management clearly prioritizes long-term vision over immediate shareholder returns—bold strategy, sure, but it leaves you wondering if the downside risk is being properly priced in. When leadership takes such an aggressive stance on R&D spending and capital allocation, retail investors end up just crossing fingers and hoping the bet pays off. Short-term volatility? Brutal. Multi-year thesis? Maybe worth the pain. Either way, this is what it means to back a visionary bet with your capital.